The health and wellness industry is undergoing a significant shift as major players realign around weight loss pharmaceuticals, female-specific diagnostics, and early-stage innovation. Novo Nordisk and Hims & Hers have reached a legal truce, resulting in Hims transitioning to offer branded, FDA-approved GLP-1 medications like Ozempic and Wegovy while restricting the use of compounded alternatives. Simultaneously, WHOOP is capitalizing on a 150% year-over-year increase in female users by launching a diagnostic suite that integrates blood testing for 11 hormonal biomarkers with wearable data and AI coaching. These developments coincide with the global wellness economy surpassing $7 trillion, a milestone marked by the release of the Fitt Insider Scouting Report, which identifies 50 startups across mental, physical, and environmental health sectors that are defining the next wave of market opportunity.
Sign in to continue reading, translating and more.
Continue
